Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Exclusion Criteria

• •Prior treatment with certain BRAF dimer inhibitors
• •Female participant is pregnant or lactating
• •Received any prior or concurrent medications or therapies known to be prohibited with DCC-3084 within 14 days
• •Received any prior antitumor therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-3084
• •Known allergy or hypersensitivity to any component of the study drug
• •Invasive malignancy within 2 years prior to the first dose of study drug other than the study indication or specific types of cancer treated with curative intent
• •Have not recovered from all clinically relevant toxicities from prior therapy
• •Impaired cardiac function
• •History of recent thrombotic or embolic events
• •Malabsorption syndrome or other illness that could affect oral absorption
• •Major surgery within 28 days of the first dose of study drug
• •Has known co-occurring mutation of KRAS, HRAS, NRAS, NF1, epidermal growth factor receptor, Phosphoinositide-3-kinase, catalytic, alpha polypeptide (PI3KCA), or Phosphatase and TENsin homolog deleted on chromosome 10 (PTEN)